Appian Medical

Appian Medical will develop and commercialize FDA cleared mHealth diagnostic technologies for sale directly to consumers.The first one will be a validated neural network algorithm (using a smartphone app) that accurately diagnoses obstructive sleep apnea (OSA) via analysis of snore recordings. Our second technology will focus on one of the 36 different chronic/costly co-morbid diseases that afflict the 100M undiagnosed OSA patients globally.

OSA is a serious sleep disorder affecting 20M adults in the US & 100M globally.US payers spend >$4B annually on diagnostic tests.Untreated OSA causes/worsens >36 chronic diseases including hypertension,diabetes, Afib,stroke, CHF, depression, ED, certain cancers, heart attack.Untreated OSA causes 7x increase in injury/death from vehicle accidents. 85% of sufferers remain undiagnosed, due to discomfort, inconvenience & high cost of sleep lab tests.

Appian has licensed a patent-protected, clinically proven technology that can diagnose OSA via smartphone in the comfort of one’s own bedroom. The software employs neural network algorithms to analyze sleep breathing sounds caused by airway collapse during apnea. In published clinical studies, it has demonstrated 93% accuracy in comparison to PSG and has the potential to replace PSG & home sleep tests globally as the standard for OSA diagnosis.

Globally it is estimated that 100M have OSA. In the US, 100M snore, while an estimated 20M have moderate-severe OSA and are candidates for medical treatment. OSA is comorbid with >36 diseases and prevalence is comparable diabetes, however recent studies have shown that as many as 85% of those with OSA have not yet been diagnosed or treated. The target market will be adults who snore or are at risk for OSA and who have smartphones.

Company’s Keywords:

mhealth, medical device, healthcare it, artificial intelligence, software, medical technology, diagnostics, health, wellness, big data